Lynn A. Hyde

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 417 citations

Life Sciences, Neuroscience, Pharmacology +17

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 337 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 165 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

Jared N. Cumming, Elizabeth M. Smith, Lingyan Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 154 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Nicholas B. Hastings, Xiaohai Wang, Lixin Song et al. · Molecular Neurodegeneration · 2017 · 154 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17